Oncimmune Holdings Valuation
Is ONC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
[object Object] Score2/6
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ONC?
Other financial metrics that can be useful for relative valuation.
|What is ONC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ONC's PS Ratio compare to its peers?
|Company||PS||Estimated Growth||Market Cap|
DDDD 4D pharma
OPTI OptiBiotix Health
TRX Tissue Regenix Group
AREC Arecor Therapeutics
ONC Oncimmune Holdings
Price-To-Sales vs Peers: ONC is good value based on its Price-To-Sales Ratio (8x) compared to the peer average (30.6x).
Price to Earnings Ratio vs Industry
How does ONC's PE Ratio compare vs other companies in the GB Biotechs Industry?
Price to Sales Ratio vs Fair Ratio
What is ONC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||8x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ONC's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ONC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ONC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ONC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
- Take a look at our analysis of ONC's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Oncimmune Holdings regulatory filings.
- Potentially undervalued companies in the Pharmaceuticals & Biotech industry.